MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Molecular Cancer Therapeutics
Marielle FournelZuomei Li

Abstract

Nonselective inhibitors of human histone deacetylases (HDAC) are known to have antitumor activity in mice in vivo, and several of them are under clinical investigation. The first of these, Vorinostat (SAHA), has been approved for treatment of cutaneous T-cell lymphoma. Questions remain concerning which HDAC isotype(s) are the best to target for anticancer activity and whether increased efficacy and safety will result with an isotype-selective HDAC inhibitor. We have developed an isotype-selective HDAC inhibitor, MGCD0103, which potently targets human HDAC1 but also has inhibitory activity against HDAC2, HDAC3, and HDAC11 in vitro. In intact cells, MGCD0103 inhibited only a fraction of the total HDAC activity and showed long-lasting inhibitory activity even upon drug removal. MGCD0103 induced hyperacetylation of histones, selectively induced apoptosis, and caused cell cycle blockade in various human cancer cell lines in a dose-dependent manner. MGCD0103 exhibited potent and selective antiproliferative activities against a broad spectrum of human cancer cell lines in vitro, and HDAC inhibitory activity was required for these effects. In vivo, MGCD0103 significantly inhibited growth of human tumor xenografts in nude mice in a dose...Continue Reading

References

Nov 12, 1996·Proceedings of the National Academy of Sciences of the United States of America·W M YangE Seto
Apr 18, 1998·Proceedings of the National Academy of Sciences of the United States of America·V M RichonP A Marks
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·A SaitoO Nakanishi
Apr 17, 1999·The Journal of Biological Chemistry·W FischleE Verdin
Apr 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·C M GrozingerS L Schreiber
Oct 19, 1999·Molecular and Cellular Biology·A H WangX J Yang
Aug 3, 2000·FEBS Letters·I Van den WyngaertS U Kass
Jan 5, 2001·Experimental Cell Research·S G Gray, T J Ekström
Sep 6, 2001·Proceedings of the National Academy of Sciences of the United States of America·X ZhouV M Richon
Oct 26, 2001·The Journal of Biological Chemistry·Hung-Ying KaoRonald M Evans
Dec 26, 2001·Japanese Journal of Cancer Research : Gann·J H ChoiD Y Kim
Mar 21, 2002·Nature Reviews. Cancer·P MarksW K Kelly
Jun 4, 2002·Current Opinion in Hematology·Ari Melnick, Jonathan D Licht
May 2, 2003·Annals of the New York Academy of Sciences·Sam ThiagalingamJose F Ponte
Sep 17, 2003·The Journal of Pharmacology and Experimental Therapeutics·Erding HuMichael Jaye
Sep 25, 2003·International Journal of Cancer. Journal International Du Cancer·Hideki KawaiHava Karsenty Avraham
Oct 3, 2003·Biochemical and Biophysical Research Communications·Keith B GlaserSteven K Davidsen
Jan 27, 2004·Journal of Leukocyte Biology·Stephen W BuckJeffrey S Smith
Mar 26, 2004·The Prostate·Kalipso HalkidouCraig N Robson
May 18, 2004·Cancer Cell·Ping ZhuMartin Göttlicher
Jun 21, 2005·The International Journal of Biochemistry & Cell Biology·Lucia AltucciHinrich Gronemeyer
Aug 27, 2005·Current Opinion in Chemical Biology·John M Denu
Jan 7, 2006·Nature Reviews. Cancer·Saverio Minucci, Pier Giuseppe Pelicci
Sep 7, 2006·Nature Reviews. Drug Discovery·Jessica E BoldenRicky W Johnstone
Mar 14, 2007·Anti-cancer Drugs·Claude Monneret
Apr 25, 2007·International Journal of Cancer. Journal International Du Cancer·Thomas BeckersKarl Sanders
May 2, 2007·Molecular and Cellular Biology·Silvia SeneseSusanna Chiocca
Oct 19, 2007·Journal of Medicinal Chemistry·Oscar M MoradeiJeffrey M Besterman

❮ Previous
Next ❯

Citations

Sep 17, 2013·Cancer Chemotherapy and Pharmacology·Vasiliki PettaKonstantinos Syrigos
Dec 4, 2010·Investigational New Drugs·Daniela Buglio, Anas Younes
Dec 7, 2010·Investigational New Drugs·Jasmine Zain, Owen A O'Connor
Aug 1, 2009·Clinical Reviews in Allergy & Immunology·Moshe Szyf
Jun 11, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Maribel CottoEileen Pacheco
Jun 22, 2010·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yoshihiro MinamiyaJunichi Ogawa
Sep 27, 2012·Journal of Medicinal Chemistry·Joel A BergmanAlan P Kozikowski
Nov 16, 2011·Immunology and Cell Biology·Bandar Ali SulimanBryan R G Williams
May 31, 2013·Proceedings of the National Academy of Sciences of the United States of America·Bradley S FergusonTimothy A McKinsey
May 4, 2010·Anti-cancer Drugs·Katarina Sebova, Ivana Fridrichova
Aug 5, 2010·Current Opinion in Oncology·Amanda CopelandAnas Younes
Aug 9, 2012·Current Opinion in Oncology·Amanda Copeland, Anas Younes
Feb 16, 2012·Cornea·Luiz Filipe de A AlvesMiguel N Burnier
May 27, 2009·Current Opinion in Hematology·Kevin PetrieSamuel Waxman
Oct 15, 2008·Annual Review of Pharmacology and Toxicology·Moshe Szyf
Feb 15, 2011·Journal of Biomedicine & Biotechnology·Riccardo MasettiAndrea Pession
Dec 10, 2013·Hematology·Connie Lee Batlevi, Anas Younes
Jun 1, 2011·Cancer Management and Research·Nadine Martinet, Philippe Bertrand
Feb 23, 2013·World Journal of Gastroenterology : WJG·Ioannis KoutsounasStamatios Theocharis
May 1, 2012·Pharmaceutical Patent Analyst·Sophia N OnonyeDennis L Wright
May 2, 2014·BMC Biology·Catherine PfefferliChantal Wicky
Mar 16, 2012·Future Medicinal Chemistry·Berkley E GryderAdegboyega K Oyelere
Jul 31, 2013·Epigenomics·Melanie R HasslerGerda Egger
Jan 1, 2014·Journal of Molecular and Cellular Cardiology·Sarah M WilliamsTimothy A McKinsey
Jun 26, 2014·Cancer Letters·Michael SchnekenburgerMarc Diederich
Apr 26, 2013·Leukemia & Lymphoma·Roman HajekMeletios Dimopoulos
May 7, 2015·Leukemia & Lymphoma·Hui YangGuillermo Garcia-Manero
Nov 27, 2009·Expert Opinion on Therapeutic Patents·Haishan Wang, Brian W Dymock
Feb 6, 2015·Expert Review of Anticancer Therapy·Patrizia Mondello, Anas Younes
Jul 24, 2010·Expert Opinion on Investigational Drugs·Takashi Watanabe
Jul 12, 2008·Expert Opinion on Investigational Drugs·Christophe Le Tourneau, Lillian L Siu
Jan 5, 2013·Expert Opinion on Drug Metabolism & Toxicology·Joanna FraczekVera Rogiers
Jan 25, 2011·Clinical Epigenetics·Julia M WagnerManfred Jung
Nov 30, 2011·The Lancet Oncology·Mark H Kirschbaum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis